Medicines for Europe letter to EC on Divisionals & Patent Linkage re Fingolimod – 13.04.2022

Open

Note on Transferable Vouchers – April 2022

Open

Advancing Medicines repurposing in the EU

Repurposing has emerged as an important strategy to address unmet medical need. Yet, there is still significant untapped potential for its application in the EU.

 

Open

Policy recommendations on uptake of biosimilar medicines in the retail market


Policy recommendations on uptake of biosimilar medicines in the retail market (November 2021)


Unlocking the potential of the biosimilar retail market (November 2021)


Retail policy algorithm: Policy recommendations to unlock the potential of the biosimilar retail market Retail policy algorithm – Paper version (November 2021)


Retail policy algorithm: Policy recommendations to unlock the potential of the biosimilar retail market Retail policy algorithm – Interactive version (November 2021)

Positioning Statements on Physician-led Switching for Biosimilar Medicines


Positioning statements on physician-led switching for biosimilar medicines (October 2021)


Biosimilar medicines group position on physician-led switching (July 2015)


Biosimilar medicines group position on biologic pharmacy substitution (September 2020)

The Issue of Abuses of Divisional Patent Application

Open

EU industrial policy can dramatically improve medicines manufacturing resilience and security of supply

Open

Medicines for Europe Position on IP Action Plan – March 2021

Open

Maintaining the exchange of critical health data – An adequacy decision on the UK data protection regime

Open

Medicines for Europe Position Paper On Patent Linkage

Open

Medicines For Europe